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Over a discussion about my project, Screening and Early Evaluation of Kidney Disease, or SEEK, a colleague questioned me on whether involve-
ment in research and educational initiatives in 
the developing world added value. Would it make 
a difference to my career? Why not let the local 
academic people in India do the work and instead 
focus my time in the United States?
These questions started me thinking about what 
motivates some of us in pursuing initiatives in the 
developing world, or donating money, or return-
ing to our country of origin. Simply put, why do 
we do it?
Over 1500 nephrologists represent the South 
Asian nephrology diaspora in the United States. 
This is twice the number of nephrologists who 
practice in India, Pakistan, and Bangladesh com-
bined. In these South Asian countries, on average, 
one nephrologist provides care for approximately 
2 million of the population. Consequently, in the 
United States, and more broadly in the West, we 
present a large resource to our countries of origin 
in South Asia.
Take the question of the motivation to help one’s 
native country. I asked this of Jai Radhakrishnan, 
a senior nephrologist at Columbia Univer-
sity Medical Center, New York. His response: 
“Gurudakshina—a way of conveying thanks for 
the wonderful education I received.” Gurudakshina 
has been defined1 as the tradition of repaying one’s 
teacher after a period of study (brahmacharya) or 
the completion of formal education. This tradition 
is one of acknowledgment, respect, and thanks. It 
is a form of reciprocity and exchange between a 
student and a teacher. The repayment is not exclu-
sively monetary and may be the performance of a 
special task or activity.
Some have done voluntary service for much 
of their professional lives. An example is Hamid 
Rabb, vice chairman of the Department of Medi-
cine at Johns Hopkins in Baltimore. Hamid began 
volunteering in medical school in Bangladeshi vil-
lages, assisting more senior doctors in doing pri-
mary care. Toward the end of medical school he 
worked in a leper colony and the famous cholera 
research institute in Dhaka. He says, “I did this to 
gain experience and give back to the area that I had 
origins in. When I was a resident I did volunteer 
work in the village, again doing primary care. As a 
renal fellow, I did work on the public renal wards in 
Bangladesh and also worked with the health min-
istry regarding curriculum and education.” Hamid 
has continued volunteer work at a more subspe-
cialty level over the years in the public hospitals in 
Bangladesh. Hamid’s volunteerism probably had 
little impact on his successful career.
Like Jai Radhakrishnan and Hamid Rabb and 
many others, I have remained in the United States, 
and tried to give back. Some of our colleagues 
returned home and made major contributions 
from there. Tazeen Jafar, who trained as a fellow at 
Tufts–New England Medical Center, returned to 
Pakistan, where she now holds an endowed chair 
in nephrology at Aga Khan University. She has 
improved the recognition and treatment of hyper-
tension and chronic kidney disease in Pakistan. In 
her most recent paper, Tazeen reports the results of 
a cluster randomized controlled trial demonstrat-
ing the efficacy of home health education in the 
treatment of hypertension in a Pakistani popu-
lation.2 Imagine the immensity of the challenge 
of completing her project in Pakistan, a country 
where international sports teams fear to venture, 
and where personal safety is endangered daily.
Another colleague, Bharat Shah, trained at 
Tufts–New England Medical Center and returned 
to India in 1988. Bharat felt he could make a big-
ger difference in India than in the United States. 
In 1993, Bharat set up the Narmada Kidney Foun-
dation, which he runs with his wife. Narmada is 
now one of the largest charitable kidney founda-
tions in India and each year conducts the Trans-
plant Games for its kidney donors and recipients. 
Likewise, Georgi Abraham, a senior nephrologist 
in Chennai, India, returned from Toronto to start 
two kidney foundations and begin a peri toneal 
dialysis practice in India.
Other colleagues had the opportunity to emi-
grate, but never did. On two separate visits to 
Muljibhai Patel Urological Hospital (MPUH) in 
Nadiad, Gujarat, India, I saw the work that Mohan 
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Rajapurkar has done there. Mohan has spent more 
than 30 years of his life at MPUH, spurning the 
opportunity to work in the United Kingdom. He 
proudly showed me the reverse osmosis system 
he built for the dialysis unit. “I am a tinkerer,” he 
says. MPUH is now a national center for nephrol-
ogy care. Perhaps the most outstanding example 
of devotion to developing Indian nephrology by 
remaining in the country is that of Kirpal Chugh at 
the Postgraduate Institute of Medical and Research, 
Chandigarh. Dr. Chugh is regarded by many as the 
father of Indian nephrology, training hundreds of 
nephrologists and pioneering kidney biopsy, dialy-
sis, and transplantation in India.
Besides providing clinical expertise to 
nephrology centers in South Asia, some have 
helped set up a dialysis unit, or made substantial 
donations to support research. Brian Pereira, a past 
president of the US National Kidney Foundation, 
has along with his son and daughter set up a new 
dialysis unit at St. John’s Hospital in Bangalore, as 
well as units elsewhere in India. Murli Acharya, 
in private nephrology practice in Hudson, Florida, 
has donated thousands of dollars to a nonprofit 
mission in Karnataka for kidney disease screen-
ing. Yet many others, too numerous to name, have 
visited periodically to teach students and col-
leagues, frequently paying their own airfare and 
living expenses.
Trainees come to the United States from South 
Asia for further experience. For example, an Inter-
national Society of Nephrology (ISN) fellowship 
award provides two years of support for clinical or 
basic research training. Several senior nephrolo-
gists have hosted trainees from South Asian coun-
tries. This too must be recognized as an important 
contribution to improving nephrology back home. 
Says Pravin Singhal, chief of nephrology at Long 
Island Jewish Medical Center in New York, who 
has hosted many trainees from India: “One may 
have guilty feelings that you did not pay back what 
your country did for you. For some it may be a 
payback.” I recently asked Professor John Feehally, 
president-elect of the ISN, how recipients of an 
ISN fellowship benefit from training abroad. His 
response was that these fellowships are transforma-
tive—profoundly changing how the trainees view 
their work when they return home.
What about the question of the academic value of 
research in a developing country? Vikas Sukhatme, 
chief academic officer at Beth Israel Deaconess 
Medical Center and Harvard Medical School, has a 
view on this. Vikas is the founder and CEO of Glo-
balCures Inc., based in Massachusetts, a not-for-
profit organization focusing on identifying novel 
uses for existing drugs and on developing thera-
pies that may bring ‘inadequate’ financial reward. 
Such approaches could affect patient care in both 
developing and developed nations. Says Sukhatme, 
“There will be value added to your career if you are 
doing novel things, whether in teaching, research or 
in clinical practice, and developing countries offer 
many challenges and opportunities for doing this.” 
He goes on, “In fact, the conditions in these coun-
tries may ‘force’ you to develop new approaches 
or technologies (for example, faster, cheaper, more 
robust diagnostics) that could later be adapted to 
the developed world.”
There are challenges in working in developing 
countries such as India. For one, the time that 
clinicians have to do research is very limited. The 
burden of clinical work is great, and there are very 
limited resources in financially stretched govern-
ment hospitals. Basic research is even more chal-
lenging because of limits on infrastructure and 
research funding. Other challenges include lack 
of regulatory oversight, limited standardization 
of research practices, and difficulties in obtaining 
informed consent from subjects because of lan-
guage or education barriers.
However, the opportunity for research in the 
developing world, and more specifically for clinical 
trials, is enormous. Very few scientists have lev-
eraged this opportunity as well as Salim Yusuf at 
McMaster University in Hamilton, Canada. Yusuf 
has published 14 papers on risk factors for heart 
disease among about 25,000 people in 55 countries 
(INTERHEART study).
Yusuf ’s paper on The Indian Polycap Study 
(TIPS)3 demonstrates the feasibility of high-quality 
patient-oriented research in India. TIPS is a double-
blind trial that tested the efficacy of a capsule, 
Polycap, consisting of low doses of thiazide, aten-
olol, ramipril, simvastatin, and aspirin, against 
individual or limited combinations of these drugs. 
Polycap conveniently and successfully reduced 
blood pressure and cholesterol.
South Asian countries provide access to a large 
pool of patients, drawing from a population of 
over 1.3 billion. The cost of enrolling subjects from 
developing countries is very low—a few cents on 
the dollar—in comparison with centers in the 
United States. Recruiting subjects from developing 
countries strengthens the research project because 
it enhances the generalizability of the findings. 
Increasingly, as well, it is recognized that genomic 
differences in populations may influence the effect 
of pharmaceuticals used for the treatment of vari-
ous diseases. Demonstrating that a drug works in 
the developing world with efficacy and safety simi-
lar to that seen in the United States makes it more 
marketable globally.
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Countries where consanguinity is common, 
such as some communities in India, present a 
great opportunity for research into rare genetic 
diseases. Verma4 makes this point. In India there 
is a high prevalence of genetic disorders. An esti-
mated 495,000 infants with congenital malforma-
tions, 390,000 with G6PD deficiency, 21,400 with 
Down’s syndrome, 9000 with β-thalassemia, 5200 
with sickle-cell disease, and 9760 with amino acid 
disorders are born each year, providing a great 
laboratory to study genetic disorders.
Whether the motivation is altruism, or gurudak-
shina, or simply leveraging an opportunity for 
research, or a combination of all of the above, I 
submit that these contributions do not need to be 
made for career-minded reasons alone—giving 
back is important enough. The Bhagavad Gita 
describes this as the grihastha ashrama (service to 
others) phase of life.5
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